Acute Myelogenous Leukemia Clinical Trials 2023

Acute Myelogenous Leukemia Clinical Trials 2023

Acute Myelogenous Leukemia research studies recruiting patients in 2023 need your help. Receive premium care & cutting edge treatments by enrolling in acute myelogenous leukemia clinical trials today.

Trials for Acute Myeloid Leukemia Patients

Trials for Acute Promyelocytic Leukemia Patients

Phase 3 Trials

Trials With No Placebo

Frequently Asked Questions

Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the 'trial drug' — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
Is there any support for travel costs?
Many of the teams running clinical trials will cover the cost of transportation to-and-from their care center.
Will I know what medication I am taking?
This depends on the specific study. If you're worried about receiving a placebo, you can actively filter out these trials using our search.
How long do clinical trials last?
Some trials will only require a single visit, while others will continue until your disease returns. It's fairly common for a trial to last somewhere between 1 and 6 months.
Do you verify all the trials on your website?
All of the trials listed on Power have been formally registered with the US Food and Drug Administration. Beyond this, some trials on Power have been formally 'verified' if the team behind the trial has completed an additional level of verification with our team.
How quickly will I hear back from a clinical trial?
Sadly, this response time can take anywhere from 6 hours to 2 weeks. We're working hard to speed up how quickly you hear back — in general, verified trials respond to patients within a few days.

Introduction to acute myelogenous leukemia

What are the top hospitals conducting acute myelogenous leukemia research?

In the battle against acute myelogenous leukemia (AML), several leading hospitals are at the forefront of groundbreaking clinical trials. At Loyola University Medical Center in Maywood, Illinois, researchers are actively engaged in 10 AML trials, building on a strong foundation of 28 completed studies since their first recorded trial in 2000. Similarly dedicated to advancing AML treatment is M D Anderson Cancer Center in Houston, Texas, which currently has 10 ongoing trials and an impressive track record of 93 past investigations dating back to 1999. The University of Chicago Comprehensive Cancer Center also plays a pivotal role with its own set of 10 active AML trials and a total count of 25 previous studies conducted since they initiated their first trial in this field in 2003.

Meanwhile, Memorial Sloan Kettering Cancer Center located in New york City contributes significantly to the progress made against AML with nine ongoing clinical trials and an outstanding tally of 78 previously conducted investigations since recording their inaugural trial for this condition back in the year2002. Notably thriving as well is Roswell Park Cancer Institute situatedin Buffalo where there are nine current acute myelogenous leukemia tests going strong while standing out among all these renowned facilities by having played a part incompleting an astounding numberof107 prior researches starting fromback as earlyas1997!

These top-tier hospitals across different locations embody hope for those affected by AML as they tirelessly work towards finding more effective treatments and ultimately a cure for this aggressive blood cancer. Their collective efforts highlight significant strides being taken toward improving patient outcomes while underscoring the importance of continued research and innovation within the medical community

Which are the best cities for acute myelogenous leukemia clinical trials?

When it comes to acute myelogenous leukemia (AML) clinical trials, several cities emerge as top contenders in advancing research and treatment options. Chicago, Illinois leads the pack with 53 active trials focusing on promising therapies such as Dasatinib, AG-120, and Lenalidomide. Following closely behind is Boston, Massachusetts with 47 ongoing studies investigating treatments like AG-120, CC-90009, and other interventions. Houston, Texas also shows promise with 45 active trials exploring Dasatinib, CC-486, CC-90009 among others for AML patients. These cities provide individuals diagnosed with AML access to cutting-edge clinical trials that hold potential for improved outcomes and novel therapeutic approaches.

Which are the top treatments for acute myelogenous leukemia being explored in clinical trials?

Exciting advancements are taking place in clinical trials exploring treatments for acute myelogenous leukemia. Among the top contenders is a pharmacological study, which currently has five active trials dedicated to this form of leukemia and an impressive 35 all-time trials since its initial listing in 2006. Another promising option is dasatinib, with three ongoing trials and a total of 12 historical clinical studies focused on acute myelogenous leukemia since it was first listed in 2009. Additionally, rituximab is showing potential with three active trials and 11 previous studies specifically targeting this type of leukemia since its introduction in 2013. Notably, cyclophosphamide also holds promise as a treatment for acute myelogenous leukemia, boasting involvement in three current trials and an extensive portfolio of 76 historical studies dating back to its initial listing in 2000. These advancements provide hope for patients battling this challenging disease.

What are the most recent clinical trials for acute myelogenous leukemia?

Recent clinical trials offer promising prospects for individuals with acute myelogenous leukemia, a challenging form of blood cancer. Regimen A, which combines TBI, Thiotepa, and Cyclophosphamide, has entered Phase 2 trials and demonstrates potential as an effective treatment option. Additionally, Flotetuzumab has shown promise in Phase 1 trials as a targeted therapy for acute myelogenous leukemia. Another experimental drug under investigation is JNJ-75276617, also in its Phase 1 trial stage. Lastly, DSP-5336 and CC-95251 are other compounds being studied at varying stages to explore their efficacy against this aggressive disease. With these advancements on the horizon, there is hope for improved outcomes and better quality of life for those battling acute myelogenous leukemia.

What acute myelogenous leukemia clinical trials were recently completed?

Recent clinical trials for acute myelogenous leukemia have made significant strides in advancing treatment options. In June 2021, AbbVie completed a trial investigating Lemzoparlimab's potential to combat this aggressive form of leukemia. Likewise, Pfizer concluded their Azacitidine study in May 2021. Bhavana Bhatnagar successfully wrapped up the Dubermatinib trial in November 2020, while Rutgers, The State University of New jersey completed their Salsalate investigation in October 2020. These groundbreaking trials underline the ongoing efforts to improve outcomes and provide hope for patients battling acute myelogenous leukemia.